Target intelligence / Profile preview

Protein-L-isoaspartate O-methyltransferase (PCMT1)

Target
PCMT1
Molecular classification
Enzyme, Protein carboxyl methyltransferase (Type II), Histone modification enzyme (methyltransferase activity for H4D24)[3][4]
01

Overview

Protein-L-isoaspartate O-methyltransferase (PCMT1) is a widely conserved protein repair enzyme that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to abnormal D-aspartyl and L-isoaspartyl residues. These abnormal residues arise from spontaneous damage, such as deamidation or isomerization, which increases with aging and stress. PCMT1 thus converts these damaged protein sites back to the normal L-aspartate configuration, maintaining protein integrity and protecting cells from dysfunction. This enzyme is highly active in both cytoplasmic and extracellular regions, especially in long-lived and membrane-associated proteins. It plays critical roles in the nervous system—where loss leads to seizures and early death in animal models—and is implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer’s. PCMT1 also modifies histone H4 at aspartate 24, linking its activity to chromatin aging and degradation. Genetic variations in PCMT1 have associations with developmental disorders like spina bifida and reproductive conditions such as premature ovarian failure. While not directly targeted by drugs, PCMT1’s repair activity is essential for cellular viability under oxidative stress and contributes to tissue-specific and systemic protein maintenance[1][2][3][4][5][6].

Other names
Protein-L-isoaspartyl(D-aspartate) O-methyltransferasePIMTL-isoaspartyl protein carboxyl methyltransferaseProtein L-isoaspartyl/D-aspartyl methyltransferaseProtein-beta-aspartate methyltransferaseEpididymis secretory sperm binding protein
02

Mechanism of action

Methyltransferase activity: Catalyzes the methylation of abnormal D-aspartyl and L-isoaspartyl residues using S-adenosyl-L-methionine (SAM) as the methyl donor, producing S-adenosyl-L-homocysteine and a methyl ester intermediate, which is then hydrolyzed to restore L-aspartate[1][2][4][5][6]. - Repair cycle: Damaged protein residues are converted back to their normal form through cyclic methylation and hydrolysis[6]. - Histone methylation: Methylates aspartate residues in histone H4, affecting chromatin aging and degradation[3].

03

Biological functions

Protein repair (restores abnormal isoaspartate and D-aspartate residues to L-aspartate)[1][2][4][5][6]Maintenance of protein structural integrity, especially in long-lived proteins[1][2][6]Protection against age-associated protein damage[1][4]Regulation of cellular metabolic response to oxidative stress[6]Histone modification (methylation of H4 at D24)[3]
04

Disease associations

Neurodegenerative disease (Alzheimer's disease)[1][4][5]Spina bifida[4][5]Premature ovarian failure[4]Aging[1][5](Possible) Cardiovascular disease and general cell stress, based on oxidative damage role[6]
05

Safety considerations

No specific therapeutic safety data, as PCMT1 is not a direct drug target in current clinical use.Knockout or deficiency leads to serious outcomes: PCMT1 null mice develop fatal seizures and premature death due to accumulation of damaged proteins, especially in neural tissues[1][4].Consequences of low activity may include accelerated aging and neurodegeneration due to protein damage accumulation[1][4][5][6].
06

Interacting drugs

No direct therapeutic drugs targeting PCMT1 are reported in current databases or literature as of June 2024. Research focuses primarily on its pathway functions and repair activity[1][4][5][6].
07

Biomarkers

Accumulation of isoaspartate residues in proteins (for example, abnormal levels in serum may indicate decreased PCMT1 activity or function)[1][2][4].PCMT1 expression levels in tissues (altered in disease states such as alcoholic liver disease)[1].

Beyond the preview

Go deeper on Protein-L-isoaspartate O-methyltransferase (PCMT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein-L-isoaspartate O-methyltransferase (PCMT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call